Comparing PLAYSTUDIOS (NASDAQ:MYPS) and Certara (NASDAQ:CERT)

PLAYSTUDIOS (NASDAQ:MYPS) and Certara (NASDAQ:CERT) are both consumer discretionary companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Valuation and Earnings

This table compares PLAYSTUDIOS and Certara”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PLAYSTUDIOS	$310.89 million	0.75	-$19.39 million	($0.19)	-9.84
Certara	$354.34 million	6.02	-$55.36 million	($0.20)	-66.30

PLAYSTUDIOS has higher earnings, but lower revenue than Certara. Certara is trading at a lower price-to-earnings ratio than PLAYSTUDIOS, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

37.5% of PLAYSTUDIOS shares are held by institutional investors. Comparatively, 74.0% of Certara shares are held by institutional investors. 14.3% of PLAYSTUDIOS shares are held by company insiders. Comparatively, 2.4% of Certara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares PLAYSTUDIOS and Certara’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PLAYSTUDIOS	-8.75%	-9.15%	-7.29%
Certara	-8.34%	3.43%	2.33%

Risk and Volatility

PLAYSTUDIOS has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Certara has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for PLAYSTUDIOS and Certara, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PLAYSTUDIOS	1	3	2	0	2.17
Certara	0	6	2	0	2.25

PLAYSTUDIOS currently has a consensus price target of $3.63, suggesting a potential upside of 93.85%. Certara has a consensus price target of $15.92, suggesting a potential upside of 20.04%. Given PLAYSTUDIOS’s higher probable upside, analysts clearly believe PLAYSTUDIOS is more favorable than Certara.

Summary

Certara beats PLAYSTUDIOS on 8 of the 13 factors compared between the two stocks.

About PLAYSTUDIOS

PLAYSTUDIOS, Inc. develops and publishes free-to-play casual games for mobile and social platforms in the United States and internationally. The company's game portfolio includes a diverse range of titles comprising social casino, card, puzzle, and adventure games. It also offers POP! Slots, myVEGAS Slots, my KONAMI Slots, MGM Slots Live, myVEGAS Blackjack, myVEGAS Bingo, Tetris, Solitaire, Spider Solitaire, Jumbline 2, Sudoku, and Mahjong games. PLAYSTUDIOS, Inc. is headquartered in Las Vegas, Nevada.

About Certara

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.